AnaptysBio to Present at the 2020 Cantor Global Virtual Healthcare Conference
September 11 2020 - 3:05PM
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage
biotechnology company developing first-in-class antibody product
candidates focused on unmet medical needs in inflammation, today
announced that Hamza Suria, chief executive officer
of AnaptysBio, will present at the 2020 Cantor Global Virtual
Healthcare Conference on Thursday, September 17,
2020 at 12:00 p.m. ET. The conference will be conducted
virtually, and the presentation will be available via
https://www.webcaster4.com/Webcast/Page/2495/37348
A live webcast of the presentation will also be available
through the investor section of the AnaptysBio website at
https://www.anaptysbio.com. A replay of the webcast will be
available for 90 days following the event.
About AnaptysBio
AnaptysBio is a clinical-stage biotechnology company
developing first-in-class antibody product candidates focused on
emerging immune control mechanisms applicable to inflammation and
immuno-oncology indications. The Company’s proprietary
anti-inflammatory pipeline includes its anti-IL-36R antibody
imsidolimab, previously referred to as ANB019, for the treatment of
rare inflammatory diseases, including generalized pustular
psoriasis, or GPP, palmoplantar pustulosis, or PPP, EGFRi-mediated
skin toxicities and ichthyosis; its anti-IL-33 antibody etokimab,
previously referred to as ANB020, for the treatment of chronic
rhinosinusitis with nasal polyps, or CRSwNP, and eosinophilic
asthma; its anti-PD-1 agonist program, ANB030, for treatment of
certain autoimmune diseases where immune checkpoint receptors are
insufficiently activated; and its BTLA modulator program, ANB032,
which is broadly applicable to human inflammatory diseases
associated with lymphoid and myeloid immune cell dysregulation.
AnaptysBio’s antibody pipeline has been developed using its
proprietary somatic hypermutation, or SHM platform, which uses in
vitro SHM for antibody discovery and is designed to replicate key
features of the human immune system to overcome the limitations of
competing antibody discovery technologies. AnaptysBio has
also developed multiple therapeutic antibodies in an
immuno-oncology collaboration with GlaxoSmithKline, including an
anti-PD-1 antagonist antibody (dostarlimab, GSK4057190A), an
anti-TIM-3 antagonist antibody (cobolimab, GSK4069889A) and an
anti-LAG-3 antagonist antibody (GSK4074386), and an inflammation
collaboration with Bristol-Myers Squibb, including an anti-PD-1
checkpoint agonist antibody (CC-90006) currently in clinical
development.
Contact:Dennis MulroyAnaptysBio,
Inc.858.732.0201dmulroy@anaptysbio.com
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Jun 2024 to Jul 2024
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Jul 2023 to Jul 2024